Literature DB >> 29196076

Experiences and Decision Making in Hematopoietic Stem Cell Transplant in Sickle Cell Disease: Patients' and Caregivers' Perspectives.

Kirshma Khemani1, Diana Ross2, Cynthia Sinha2, Ann Haight3, Nitya Bakshi3, Lakshmanan Krishnamurti4.   

Abstract

Sickle cell disease (SCD) is one of the most commonly inherited hemoglobin disorders that has a significant impact on quality of life, increased childhood morbidity, and premature mortality. Currently, hematopoietic stem cell transplant (HSCT) is the only treatment with a curative intent. The objective of this study was to determine patients' and caregivers' knowledge of HSCT, the factors influencing the decision to pursue HSCT, their experiences, and the impact of a successful HSCT on their daily living. At Children's Healthcare of Atlanta, we conducted a qualitative study using a semistructured interview guide of patient-caregiver dyads and 2 focus-group sessions of adult long-term survivors of HSCT to elicit key factors in decision making, their experiences with HSCT, and the impact of HSCT. Interviews and focus-group sessions were recorded and transcribed verbatim. Transcripts were coded and analyzed for emerging themes using NVivo 10.0. We enrolled 11 patient-caregiver dyads (n = 6, female patients; n = 10, mothers) in the qualitative interviews and 2 focus groups with 5 (n = 2, females) and 7 (n = 3, females) participants in each group, respectively. Our analysis revealed 3 prominent themes: (1) factors and concerns influencing HSCT decision making; (2) HSCT experiences; and (3) impact of HSCT on daily life. Participants reported that progression of disease-related complications and availability of a matched donor strongly influenced the decision to pursue HSCT. Although patients and caregivers had to deal with the arduous process of HSCT and transplant-related morbidities, participants were satisfied with their decision and expressed no decisional regrets. Decision making for HSCT for patients with SCD is a complex process. Understanding the key influential factors in decision making and the impact HSCT has on these patients and their families will generate crucial insights that can guide the care of future patients and research studies.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  Decision making; Hematopoietic stem cell transplant; Patient perspective; Qualitative study; Sickle cell disease

Mesh:

Year:  2017        PMID: 29196076     DOI: 10.1016/j.bbmt.2017.11.018

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  5 in total

Review 1.  How I treat sickle cell disease with hematopoietic cell transplantation.

Authors:  Elizabeth O Stenger; Shalini Shenoy; Lakshmanan Krishnamurti
Journal:  Blood       Date:  2019-12-19       Impact factor: 22.113

2.  Hematopoietic cell transplantation for sickle cell disease: updates and future directions.

Authors:  Lakshmanan Krishnamurti
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 3.  Evidence-Based Minireview: In young children with severe sickle cell disease, do the benefits of HLA-identical sibling donor HCT outweigh the risks?

Authors:  Niketa Shah; Lakshmanan Krishnamurti
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 4.  Genetic therapies for the first molecular disease.

Authors:  Phillip A Doerfler; Akshay Sharma; Jerlym S Porter; Yan Zheng; John F Tisdale; Mitchell J Weiss
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

5.  Motivations and Decision-Making of Adult Sickle Cell Patients in High-Risk Clinical Research.

Authors:  Hae Lin Cho; Scott Y H Kim; Courtney Fitzhugh; Matthew Hsieh; John Tisdale; Christine Grady
Journal:  Biol Blood Marrow Transplant       Date:  2020-03-19       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.